Cure My Disease

Don't miss your cure!

 Log in / Sign up

Neurodegenerative drug study ends early after only 17 participants

NCT ID NCT06111014

Terminated Disease control Sponsor: Alector Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEURODEGENERATIVE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis frontotemporal dementia neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEURODEGENERATIVE DISEASES

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria Di Modena Policlinico

    Modena, 41126, Italy

  • Centro Hospitalar E Universitario de Coimbra EPE

    Coimbra, 3000-075, Portugal

  • Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria

    Lisbon, 1649-028, Portugal

  • Dignity Health - Arizona

    Phoenix, Arizona, 85013, United States

  • Erasmus MC-Dr. Molewaterplein 40

    Rotterdam, 3015 GD, Netherlands

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35

    Milan, 20122, Italy

  • Groupe Hospitalier Pitié Salpétrière

    Paris, 75013, France

  • IRCCS - Centro S. Giovanni di Dio Fatebenefratelli

    Brescia, 25125, Italy

  • Irving Institute for Clinical and Translational Research

    New York, New York, 10032, United States

  • Karolinska Universitetssjukhuset Huddinge

    Huddinge, SE-14186, Sweden

  • Mayo Comprehensive Cancer Center - PPDS

    Rochester, Minnesota, 55905, United States

  • Parkwood Institute

    London, Ontario, N6C 0A7, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5, Canada

  • UZ Leuven

    Leuven, 3000, Belgium

  • University College London

    London, WC1NAR, United Kingdom

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio, 45219, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Universitätsklinikum Ulm - Leimgrubenweg 12-14

    Ulm, 89075, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.